methotrexate has been researched along with Lupus Erythematosus, Cutaneous, Subacute in 29 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (6.90) | 18.2507 |
| 2000's | 11 (37.93) | 29.6817 |
| 2010's | 10 (34.48) | 24.3611 |
| 2020's | 6 (20.69) | 2.80 |
| Authors | Studies |
|---|---|
| Diaz, D; Feng, R; Grinnell, M; Jobanputra, A; Keyes, E; Vazquez, T; Werth, VP | 1 |
| Chen, HW; Chong, BF; Feng, R; Sprow, G; Werth, VP | 1 |
| Desjardin, I; Meylan, M; Milhau, N; Mosca, M; Panzuti, P; Pin, D; Randleff-Rasmussen, P | 1 |
| Chen, Y; Li, H; Zhang, J | 1 |
| de Mattos, ABN; Furian, MEA; Garbo Baroni, L; Zanotto, LL | 1 |
| Bennett, C; Chen, S; Hannon, CW; Lima, HC; McCourt, C | 1 |
| Nutan, F; Ortega-Loayza, AG | 1 |
| Das, D; Nayak, C; Patil, P; Tambe, S | 1 |
| Aberer, E; Bata-Csörgő, Z; Caproni, M; Dreher, A; Frances, C; Gläser, R; Klötgen, HW; Kuhn, A; Landmann, A; Marinovic, B; Nyberg, F; Olteanu, R; Ranki, A; Szepietowski, JC; Volc-Platzer, B | 1 |
| Afif, N; Chatelus, E; Goetz, J; Lipsker, D; Sibilia, J; Sordet, C; Sparsa, L | 1 |
| Knott, HM; Martínez, JD | 1 |
| Bonsmann, G; Kuhn, A; Ruland, V | 1 |
| Fleck, M; Klein, A; Landthaler, M; Vogt, T; Wenzel, SM | 1 |
| Chang, AY; Werth, VP | 1 |
| Efthimiou, P; Kukar, M | 1 |
| Bahrami, S; Callen, JP; Hazey, MA; Wilkerson, E | 1 |
| Boehm, I; Wenzel, J | 1 |
| Böhm, I | 1 |
| Heath, M; Raugi, GJ | 1 |
| Bauer, R; Bieber, T; Brähler, S; Tüting, T; Wenzel, J | 1 |
| Wenzel, J | 1 |
| Bieber, T; Tüting, T; Uerlich, M; Wenzel, J | 1 |
| Greenberg, RG; Jackson, JM; Norman, R | 1 |
| Bauer, R; Bieber, T; Huber, A; Tüting, T; Wenzel, J | 1 |
| Tüting, T; Wenzel, J | 1 |
| Dumortier, J; Fontana, A; Guillaud, O; Hot, A; Lapalus, MG; Miossec, P; Scoazec, JY | 1 |
| Bauer, R; Böhm, L; Uerlich, M | 1 |
| Bauer, R; Boehm, GA; Boehm, IB | 1 |
| Kuhn, A; Lehmann, P; Ruzicka, T; Specker, C | 1 |
7 review(s) available for methotrexate and Lupus Erythematosus, Cutaneous, Subacute
| Article | Year |
|---|---|
Interventions for cutaneous disease in systemic lupus erythematosus.
Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine; Dermatologic Agents; Exanthema; Female; Humans; Hydroxychloroquine; Immunosuppressive Agents; Lupus Erythematosus, Cutaneous; Lupus Erythematosus, Systemic; Male; Medicine, Chinese Traditional; Methotrexate; Placebos; Quality of Life; Randomized Controlled Trials as Topic; Skin Diseases; Symptom Flare Up | 2021 |
Cutaneous Lupus: A Brief Review of Old and New Medical Therapeutic Options.
Topics: Adrenal Cortex Hormones; Antibodies, Monoclonal; Antimalarials; Calcineurin Inhibitors; Dapsone; Humans; Immunologic Factors; Lenalidomide; Lupus Erythematosus, Cutaneous; Methotrexate; Mycophenolic Acid; Retinoids; Thalidomide | 2017 |
Cutaneous lupus erythematosus: update of therapeutic options part II.
Topics: Algorithms; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Azathioprine; Clofazimine; Cyclophosphamide; Cyclosporine; Dapsone; Humans; Immunoglobulins, Intravenous; Immunosuppressive Agents; Interferon-alpha; Isoxazoles; Leflunomide; Lenalidomide; Lupus Erythematosus, Cutaneous; Methotrexate; Mycophenolic Acid; Retinoids; Rituximab; Thalidomide; Tumor Necrosis Factor-alpha | 2011 |
Treatment of cutaneous lupus.
Topics: Administration, Topical; Antimalarials; Calcineurin Inhibitors; Dapsone; Glucocorticoids; Humans; Immunosuppressive Agents; Lupus Erythematosus, Cutaneous; Methotrexate; Mycophenolic Acid; Severity of Illness Index; Sunscreening Agents; Thalidomide | 2011 |
Evidence-based evaluation of immunomodulatory therapy for the cutaneous manifestations of lupus.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antimalarials; Azathioprine; Cladribine; Cyclophosphamide; Cyclosporine; Evidence-Based Medicine; Humans; Immunoglobulin G; Immunologic Factors; Immunotherapy; Isoxazoles; Leflunomide; Lupus Erythematosus, Cutaneous; Methotrexate; Mycophenolic Acid; Rituximab; Tacrolimus; Thalidomide | 2004 |
[Systemic treatment of cutaneous lupus erythematosus].
Topics: Acute Disease; Administration, Oral; Adrenal Cortex Hormones; Adult; Antibodies, Monoclonal; Antimalarials; Azathioprine; Clinical Trials as Topic; Cyclophosphamide; Dapsone; Dermatologic Agents; Female; Gold; Humans; Immunologic Factors; Immunosuppressive Agents; Interferon-alpha; Lupus Erythematosus, Cutaneous; Male; Methotrexate; Plasmapheresis; Pregnancy; Retinoids; Thalidomide; Time Factors | 2003 |
Identification of type I interferon-associated inflammation in the pathogenesis of cutaneous lupus erythematosus opens up options for novel therapeutic approaches.
Topics: Antimalarials; Autoantibodies; Chemokines; Chloroquine; Cytokines; Humans; Immunosuppressive Agents; Inflammation Mediators; Interferon Type I; Lupus Erythematosus, Cutaneous; Methotrexate; Models, Biological | 2007 |
1 trial(s) available for methotrexate and Lupus Erythematosus, Cutaneous, Subacute
| Article | Year |
|---|---|
FACS monitoring of lymphocyte-subsets in patients with discoid and subacute-cutaneous lupus erythematosus receiving low-dose methotrexate.
Topics: Adult; Aged; CD4-CD8 Ratio; Female; Flow Cytometry; Humans; Immunosuppressive Agents; Lupus Erythematosus, Cutaneous; Lupus Erythematosus, Discoid; Lymphocyte Subsets; Male; Methotrexate; Middle Aged; T-Lymphocytes | 2002 |
21 other study(ies) available for methotrexate and Lupus Erythematosus, Cutaneous, Subacute
| Article | Year |
|---|---|
Comparative responsiveness of cutaneous lupus erythematosus patients to methotrexate and mycophenolate mofetil: A cohort study.
Topics: Cohort Studies; Humans; Immunosuppressive Agents; Lupus Erythematosus, Cutaneous; Lupus Erythematosus, Systemic; Methotrexate; Mycophenolic Acid | 2022 |
Cigarette smoking is associated with decreased long-term treatment cessation of mycophenolate mofetil and methotrexate in cutaneous lupus erythematosus.
Topics: Cigarette Smoking; Humans; Immunosuppressive Agents; Lupus Erythematosus, Cutaneous; Lupus Erythematosus, Systemic; Methotrexate; Mycophenolic Acid; Withholding Treatment | 2023 |
Long-term successful treatment of a donkey with cutaneous lupus erythematous with methotrexate.
Topics: Animals; Biopsy; Equidae; France; Lupus Erythematosus, Cutaneous; Male; Methotrexate; Skin; Treatment Outcome | 2020 |
Methotrexate-induced toxic epidermal necrolysis in a child undergoing a combination therapy for systemic lupus erythematosus.
Topics: Child; Combined Modality Therapy; Humans; Lupus Erythematosus, Cutaneous; Lupus Erythematosus, Systemic; Methotrexate; Stevens-Johnson Syndrome | 2021 |
Subacute cutaneous lupus erythematosus triggered after measles vaccination.
Topics: Antirheumatic Agents; Drug Therapy, Combination; Female; Folic Acid; Follow-Up Studies; Glucocorticoids; Humans; Hydroxychloroquine; Lupus Erythematosus, Cutaneous; Lupus Erythematosus, Systemic; Measles; Methotrexate; Middle Aged; Prednisone; Vaccination; Vitamin B Complex | 2021 |
Lupus erythematosus-lichen planus overlap syndrome in an HIV-infected individual.
Topics: Adult; Antiretroviral Therapy, Highly Active; Biopsy, Needle; Dermatologic Agents; Female; HIV Infections; Humans; Lichen Planus; Lupus Erythematosus, Cutaneous; Methotrexate; Syndrome; Treatment Outcome | 2016 |
S2k guideline for treatment of cutaneous lupus erythematosus - guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV).
Topics: Adrenal Cortex Hormones; Antimalarials; Biological Products; Calcineurin Inhibitors; Consensus; Dapsone; Humans; Immunosuppressive Agents; Lenalidomide; Lupus Erythematosus, Cutaneous; Methotrexate; Mycophenolic Acid; Practice Guidelines as Topic; Retinoids; Thalidomide | 2017 |
Jessner-Kanof disease induced by leflunomide: a dermal variant of cutaneous lupus?
Topics: Antibodies, Antinuclear; Antirheumatic Agents; Chloroquine; Female; Gold; Humans; Interleukin 1 Receptor Antagonist Protein; Isoxazoles; Leflunomide; Lupus Erythematosus, Cutaneous; Methotrexate; Middle Aged; Treatment Outcome | 2011 |
Innovative management of lupus erythematosus.
Topics: Administration, Topical; Adolescent; Adult; Anti-Inflammatory Agents; Antimalarials; Azathioprine; Calcineurin Inhibitors; Calcium; Child; Combined Modality Therapy; Cyclophosphamide; Female; Glucocorticoids; Humans; Immunosuppressive Agents; Lupus Erythematosus, Cutaneous; Lupus Erythematosus, Discoid; Lupus Erythematosus, Systemic; Male; Methotrexate; Retinoids; Therapies, Investigational; Vitamin D; Young Adult | 2010 |
Cyclosporin combined with methotrexate in two patients with recalcitrant subacute cutaneous lupus erythematosus.
Topics: Adult; Cyclosporine; Dermatologic Agents; Drug Therapy, Combination; Female; Humans; Lupus Erythematosus, Cutaneous; Methotrexate; Middle Aged; Treatment Outcome | 2011 |
Lupus pernio: sarcoid-specific cutaneous manifestation associated with chronic sarcoid arthropathy.
Topics: Adult; Antibodies, Monoclonal; Biopsy; Comorbidity; Drug Therapy, Combination; Humans; Infliximab; Lupus Erythematosus, Cutaneous; Male; Methotrexate; Prednisone; Sarcoidosis; Skin; Treatment Outcome | 2011 |
Golimumab-exacerbated subacute cutaneous lupus erythematosus.
Topics: Aged; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antirheumatic Agents; Chloroquine; Desonide; Drug Eruptions; Female; Humans; Lupus Erythematosus, Cutaneous; Methotrexate; Prednisone | 2012 |
Decrease of B-cells and autoantibodies after low-dose methotrexate.
Topics: Adjuvants, Immunologic; Adult; Aged; Autoantibodies; B-Lymphocytes; Female; Follow-Up Studies; Humans; Lupus Erythematosus, Cutaneous; Lupus Erythematosus, Systemic; Lymphocyte Count; Lymphocyte Subsets; Male; Methotrexate; Middle Aged; Retrospective Studies; Treatment Outcome | 2003 |
Efficacy and safety of methotrexate in recalcitrant cutaneous lupus erythematosus: results of a retrospective study in 43 patients.
Topics: Adult; Aged; Aged, 80 and over; Drug Administration Schedule; Drug Evaluation; Female; Humans; Immunosuppressive Agents; Lupus Erythematosus, Cutaneous; Lymphocyte Count; Lymphopenia; Male; Methotrexate; Middle Aged; Patient Selection; Retrospective Studies; Severity of Illness Index; Treatment Outcome | 2005 |
Methotrexate in systemic lupus erythematosus.
Topics: Humans; Immunosuppressive Agents; Lupus Erythematosus, Cutaneous; Methotrexate; Retrospective Studies; Skin Physiological Phenomena; Treatment Outcome | 2005 |
Case reports of etanercept in inflammatory dermatoses.
Topics: Adult; Body Surface Area; Dermatomyositis; Drug Therapy, Combination; Etanercept; Female; Humans; Immunoglobulin G; Immunosuppressive Agents; Injections, Subcutaneous; Lupus Erythematosus, Cutaneous; Methotrexate; Middle Aged; Pemphigus, Benign Familial; Psoriasis; Quality of Life; Receptors, Tumor Necrosis Factor | 2006 |
Methotrexate treatment in cutaneous lupus erythematosus: subcutaneous application is as effective as intravenous administration.
Topics: Humans; Immunosuppressive Agents; Injections, Intravenous; Injections, Subcutaneous; Lupus Erythematosus, Cutaneous; Methotrexate; Retrospective Studies; Treatment Outcome | 2006 |
Epstein Barr virus-induced hepatitis associated with methotrexate treatment.
Topics: Chemical and Drug Induced Liver Injury; Diagnosis, Differential; Epstein-Barr Virus Infections; Female; Hepatitis, Viral, Human; Humans; Immunosuppressive Agents; Liver Function Tests; Lupus Erythematosus, Cutaneous; Methotrexate; Middle Aged; Serologic Tests | 2008 |
Rapid improvement of subacute cutaneous lupus erythematosus with low-dose methotrexate.
Topics: Adult; Dermatologic Agents; Female; Humans; Immunosuppressive Agents; Injections, Intravenous; Lupus Erythematosus, Cutaneous; Methotrexate; Treatment Outcome | 1997 |
Management of cutaneous lupus erythematosus with low-dose methotrexate: indication for modulation of inflammatory mechanisms.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Autoantibodies; Dose-Response Relationship, Drug; Female; Humans; Lupus Erythematosus, Cutaneous; Male; Methotrexate; Middle Aged; Retrospective Studies; Treatment Outcome | 1998 |
Methotrexate treatment for refractory subacute cutaneous lupus erythematosus.
Topics: Adult; Dermatologic Agents; Female; Humans; Lupus Erythematosus, Cutaneous; Methotrexate | 2002 |